CONSORTIUM TO RESEARCH GENETIC MARKERS LINKED WITH SAEs
Published Online: Thursday, November 1, 2007 [ ]
The newly formed International Serious Adverse Events
Consortium (SAEC) plans to launch 2 initial research programs
designed to identify genetic markers that may help predict
which individuals are at risk for serious drug-related adverse
The studies will address drug-related liver toxicity and the
rare but serious drug-related skin condition Stevens-Johnson
syndrome. Patients respond differently to medicines, and all
medicines can have side effects in some individuals.
The SAEC's work is based on the hypothesis that these differences
have a genetic basis, and its research studies will
examine the impact genes can have on how individuals
respond to drugs. The findings will be made available to the
research community for further study. The groups' objectives
are as follows:
- Reduce the significant patient and economic costs associated
with drug-related SAEs
- Improve the flow of safe and effective medical advances by
addressing safety issues regarding new drugs before they
enter the marketplace
- Establish common pharmacogenetic research platforms for
SAEC members and other academic institutions to determine
relationships between genetic variations and SAEs
- Encourage further study by creating a public database
SAEC is a nonprofit partnership comprised of leading pharmaceutical
companies, academic institutions, and the FDA.
Your comments are valuable to us. Thank you.
Sorry, you must be logged in and registered to post a comment.
To login, click To register, click here.